Top 13 Drug Discovery startups in UK
May 14, 2026
|
Like
22
1
Funding: $2.7B
Isomorphic Labs is a spin-off of Google DeepMind, developing and designing drugs based on the AlphaFold platform, which predicts protein structures. The company has created powerful predictive and generative AI models that simulate complex biological phenomena to aid in the development of new molecules, predicting drug effectiveness, and creating innovative drugs to treat and cure some of the world's most devastating diseases. The company also provides scientists with the freely available AlphaFold Protein Structure Database, which gives open access to over 200 million protein structure predictions to accelerate scientific research.
Isomorphic Labs is a spin-off of Google DeepMind, developing and designing drugs based on the AlphaFold platform, which predicts protein structures. The company has created powerful predictive and generative AI models that simulate complex biological phenomena to aid in the development of new molecules, predicting drug effectiveness, and creating innovative drugs to treat and cure some of the world's most devastating diseases. The company also provides scientists with the freely available AlphaFold Protein Structure Database, which gives open access to over 200 million protein structure predictions to accelerate scientific research.
2
Funding: $474.4M
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
3
Funding: $397.9M
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
4
Funding: $292M
A leading British artificial intelligence company located in the knowledge quarter of London with a focus in health and drug development
A leading British artificial intelligence company located in the knowledge quarter of London with a focus in health and drug development
5
Funding: $219.2M
Juvenescence AI is focused on developing drugs that were discovered by Artificial Intelligence Techniques.
Juvenescence AI is focused on developing drugs that were discovered by Artificial Intelligence Techniques.
6
Funding: $169.2M
Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
7
Funding: £128M
OMass Therapeutics develops new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry.
OMass Therapeutics develops new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry.
8
Funding: $93M
Causaly develops a biomedical research discovery tool designed to find and unlock key hidden evidence in biomedicine.
Causaly develops a biomedical research discovery tool designed to find and unlock key hidden evidence in biomedicine.
9
Funding: $81M
Synthace provides R&D cloud platform which supports scientists to share and access progress with the development of biopharmaceutical therapeutics
Synthace provides R&D cloud platform which supports scientists to share and access progress with the development of biopharmaceutical therapeutics
10
Funding: $73.1M
Harnessing the power of machine learning to create better protein therapeutics.
Harnessing the power of machine learning to create better protein therapeutics.
11
Funding: $11.3M
Oxford Drug Design focuses on developing and delivering services and technologies in computer-aided drug discovery.
Oxford Drug Design focuses on developing and delivering services and technologies in computer-aided drug discovery.
12
Funding: $5.5M
Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function.
Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function.
13
Funding: $3.6M
ReactWise provides an artificial intelligence Co-Pilot that facilitates the optimization of chemical processes.
ReactWise provides an artificial intelligence Co-Pilot that facilitates the optimization of chemical processes.
★
See also:
